Boone Capital Management LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Boone Capital Management LLC reported 19 stock positions worth $383.4 million. Its top holding was Unum (UNM) at 12.4% of the portfolio, followed by Globus Medical Class A (GMED, 11.4%) and Cigna (CI, 11.4%). Compared with Q1 2024, it opened 3 new positions, sold out of 5, added to 6 and reduced 9. The biggest buy was Globus Medical Class A (GMED, shares +20%) and the biggest sale an exit from Enovis (ENOV).
- Most Recent 13F
- Q2 2026
- Location
- ATLANTA, GA
- CIK
- 0001882053
- Portfolio Value
- $383.4M (Q2 2024)
- SEC Filing
- 0001214659-24-014668 ↗ filed Aug 14, 2024
Holdings Value
Holdings 19 stocks · $383.4M
| UNM Unum Group | 12.40% | 930,545 | $47.6M | Reduce -9.2% |
| GMED Globus Medical Inc. Class A | 11.38% | 637,315 | $43.6M | Add +20.3% |
| CI The Cigna Group | 11.37% | 131,926 | $43.6M | No change |
| MOH Molina Healthcare Inc. | 7.68% | 99,094 | $29.5M | Add +15.6% |
| DHR Danaher Corp. | 6.93% | 106,360 | $26.6M | Add +61.6% |
| BAX Baxter International Inc. | 6.29% | 721,278 | $24.1M | Add +3.3% |
| IQV Iqvia Holdings Inc. | 5.22% | 94,734 | $20.0M | New |
| AMPH Amphastar Pharmaceuticals Inc. | 5.17% | 495,089 | $19.8M | Reduce -18.4% |
| MIRM Mirum Pharmaceuticals Inc. | 4.67% | 523,679 | $17.9M | Add +15.9% |
| PNTG The Pennant Group Inc. | 4.23% | 699,966 | $16.2M | Add +24.1% |
| BERY Berry Global Group Inc. | 3.99% | 259,710 | $15.3M | Reduce -42.3% |
| IDYA Ideaya Biosciences Inc. | 3.86% | 422,049 | $14.8M | Reduce -20.7% |
| OFIX Orthofix Medical Inc. | 2.68% | 775,368 | $10.3M | Reduce -20.4% |
| CRL Charles River Laboratories | 2.60% | 48,288 | $10.0M | New |
| CERT Certara Inc. | 2.60% | 718,983 | $10.0M | New |
| XENE Xenon Pharmaceuticals Inc. | 2.55% | 250,460 | $9.8M | Reduce -14.1% |
| VKTX Viking Therapeutics Inc. | 2.42% | 174,766 | $9.3M | Reduce -43.7% |
| HCSG Healthcare Services Group | 2.41% | 873,018 | $9.2M | Reduce -5.8% |
| TARS Tarsus Pharmaceuticals Inc. | 1.53% | 216,047 | $5.9M | Reduce -64.5% |
Portfolio Sells Q1 2024 → Q2 2024
| ENOV Enovis Corp. | Sold out | 0.00% | −7.11 |
| BIO Bio-Rad Laboratories-A | Sold out | 0.00% | −5.06 |
| MLAB Mesa Laboratories Inc. | Sold out | 0.00% | −2.96 |
| TARS Tarsus Pharmaceuticals Inc. | Reduce -64.5% | 1.53% | −2.95 |
| VTRS Viatris Inc. | Sold out | 0.00% | −2.74 |
| VKTX Viking Therapeutics Inc. | Reduce -43.7% | 2.42% | −2.73 |
| QTRX Quanterix Corp. | Sold out | 0.00% | −1.57 |
| BERY Berry Global Group Inc. | Reduce -42.3% | 3.99% | −1.52 |
| IDYA Ideaya Biosciences Inc. | Reduce -20.7% | 3.86% | −0.86 |
| AMPH Amphastar Pharmaceuticals Inc. | Reduce -18.4% | 5.17% | −0.22 |
| OFIX Orthofix Medical Inc. | Reduce -20.4% | 2.68% | −0.18 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -14.1% | 2.55% | +0.01 |
| HCSG Healthcare Services Group | Reduce -5.8% | 2.41% | +0.07 |
| UNM Unum Group | Reduce -9.2% | 12.40% | +1.28 |
Portfolio Buys Q1 2024 → Q2 2024
| GMED Globus Medical Inc. Class A | Add +20.3% | 11.38% | +5.64 |
| IQV Iqvia Holdings Inc. | New | 5.22% | +5.22 |
| DHR Danaher Corp. | Add +61.6% | 6.93% | +3.61 |
| CRL Charles River Laboratories | New | 2.60% | +2.60 |
| CERT Certara Inc. | New | 2.60% | +2.60 |
| MIRM Mirum Pharmaceuticals Inc. | Add +15.9% | 4.67% | +2.37 |
| PNTG The Pennant Group Inc. | Add +24.1% | 4.23% | +1.99 |
| MOH Molina Healthcare Inc. | Add +15.6% | 7.68% | +0.56 |
| BAX Baxter International Inc. | Add +3.3% | 6.29% | +0.26 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 16 | $427.5M | TFX, MIRM, CI, IONS, UNH |
| Q1 2026 | 13 | $326.4M | MIRM, IONS, CI, MDT, TFX |
| Q4 2025 | 15 | $318.6M | MDT, MIRM, IONS, CI, BMRN |
| Q3 2025 | 16 | $305.0M | MDT, MIRM, IONS, CI, BBIO |
| Q2 2025 | 11 | $233.2M | MDT, MIRM, BMRN, AVTR, UNM |
| Q1 2025 | 12 | $293.8M | UNM, MDT, MIRM, GMED, CI |
| Q4 2024 | 13 | $296.5M | UNM, GMED, PRGO, MIRM, MOH |
| Q3 2024 | 17 | $385.8M | UNM, GMED, CI, MOH, CHE |
| Q2 2024 | 19 | $383.4M | UNM, GMED, CI, MOH, DHR |
| Q1 2024 | 21 | $494.4M | UNM, CI, MOH, ENOV, BAX |